COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

A Phase II Evaluation of Docetaxel and Carboplatin Followed by Tumor Volume Directed Pelvic Irradiation

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00285415
Recruitment Status : Completed
First Posted : February 2, 2006
Last Update Posted : September 16, 2019
Information provided by (Responsible Party):
Carilion Clinic

Brief Summary:
The purpose of this study is to determine the effectiveness of the combination of the two drugs, docetaxel (Taxotere®) and carboplatin (Paraplatin®) followed by radiation directed at the tumor in treating your endometrial cancer.

Condition or disease Intervention/treatment Phase
Advanced Endometrial Adenocarcinoma, Stage III A, B, C Drug: Docetaxel and Carboplatin Phase 2

Show Show detailed description

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 46 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase II Evaluation of Docetaxel and Carboplatin Followed by Tumor Volume Directed Pelvic Plus or Minus Para-Aortic Irradiation for Stage III/IV Endometrial Carcinoma
Study Start Date : April 2005
Actual Primary Completion Date : April 2012
Actual Study Completion Date : June 2012

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
1 Drug: Docetaxel and Carboplatin
docetaxel (75 mg/m2) + carboplatin (AUC 6) IV every 3 weeks X 6 cycles

Primary Outcome Measures :
  1. to estimate the overall response rate (ORR) for women with newly diagnosed stages III-IV or recurrent endometrial carcinoma treated with docetaxel and carboplatin followed by tumor volume directed pelvic plus or minus para-aortic irradiation. [ Time Frame: 6 cycles of chemotherapy followed by radiation therapy ]

Secondary Outcome Measures :
  1. To estimate the progressive free survival (PFS) [ Time Frame: every 3 months for 2 years and then every 6 months for 3 years. Yearly after 5 years. ]
  2. To estimate overall survival (OS) [ Time Frame: every 3 months for 2 years then every 6 months for 3 years ]
  3. To evaluate the safety and tolerability profile of this regimen [ Time Frame: during treatment ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 99 Years   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

- All patients with advanced endometrial adenocarcinoma, stage III A, B, C and Stage IV confined to the pelvis, and recurrent disease limited to the pelvis.

Surgical stage III and limited stage IV disease, including those patients with positive adnexa, tumor invading the serosa, positive and/or para-aortic nodes, pelvic metastases, positive pelvic washings or vaginal involvement.

Histology must be adenocarcinoma, adenosquamous cell, squamous cell, clear cell or serous papillary carcinoma

Status post surgical resection, including a hysterectomy and bilateral salpingo-oophorectomy within the past 6 weeks (Pelvic lymph node and para-aortic lymph node sampling are optional)

Patients may be sub-optimally or optimally debulked (disease < 2 cm). Patients are eligible with measurable disease or evaluable disease. All positive para-aortic node patients must be further staged by chest CT scan. If chest CT scan is negative, patients are eligible.

Patients who have met the pre-entry criteria including following lab findings:

ANC > 1500, Platelet count > 100,000/mm3, Hemoglobin ≥ 8 mg/dl, Creatinine < 2.0 mg/dl.

Total Bilirubin must be within normal limits. (WNL)

AST or ALT and Alkaline Phosphatase must be within the range allowing for eligibility

Patients who have signed an approved informed consent.

GOG Performance Grade 0, 1, or 2.

Women ≥ 18 years of age

Exclusion Criteria:

- Patients with Stage IV or recurrent disease outside of the pelvis.

Patients who have had prior pelvic or abdominal radiation therapy.

Patients with concomitant malignancy other than non-melanoma skin cancer.

Patient with a prior malignancy who have been disease-free for < 5 years or who received prior chemotherapy or radiation therapy for that malignancy.

Patients with a history of serious co-morbid illness that would preclude protocol therapy.

Patients with an estimated survival of less than three months.

Patients with parenchymal liver metastases.

Patients who received prior chemotherapy excluding low-dose methotrexate for rheumatologic reasons.

Histology consistent with uterine sarcomas, carcinosarcoma or leiomyosarcoma.

Women with baseline peripheral neuropathy Grade ≥ 2.

Women with a history of severe hypersensitivity reaction to drugs formulated with polysorbate 80.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00285415

Layout table for location information
United States, South Carolina
Gynecologic Oncology Research & Development, LLC
Greenville, South Carolina, United States, 29601
United States, Virginia
Carilion GYN Oncology Associates
Roanoke, Virginia, United States, 24014
Sponsors and Collaborators
Carilion Clinic
Layout table for investigator information
Principal Investigator: Dennis R Scribner, JR, MD
Layout table for additonal information
Responsible Party: Carilion Clinic Identifier: NCT00285415    
Other Study ID Numbers: EndoRT
WIRB PRO NUM: 20050247
First Posted: February 2, 2006    Key Record Dates
Last Update Posted: September 16, 2019
Last Verified: September 2019
Keywords provided by Carilion Clinic:
Advanced endometrial adenocarcinoma, stage III A, B, C
Additional relevant MeSH terms:
Layout table for MeSH terms
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Antineoplastic Agents
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action